EA202090250A1 - Усовершенствованная молекула полипептида с двойной специфичностью - Google Patents

Усовершенствованная молекула полипептида с двойной специфичностью

Info

Publication number
EA202090250A1
EA202090250A1 EA202090250A EA202090250A EA202090250A1 EA 202090250 A1 EA202090250 A1 EA 202090250A1 EA 202090250 A EA202090250 A EA 202090250A EA 202090250 A EA202090250 A EA 202090250A EA 202090250 A1 EA202090250 A1 EA 202090250A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide molecule
improved double
double specificity
specificity polypeptide
binding region
Prior art date
Application number
EA202090250A
Other languages
English (en)
Inventor
Мартин Хофманн
Феликс Унвердорбен
Себастиан Бунк
Доминик Маурер
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Priority claimed from PCT/EP2018/069151 external-priority patent/WO2019012138A1/en
Publication of EA202090250A1 publication Critical patent/EA202090250A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к биспецифической молекуле полипептида, содержащей первую полипептидную цепь и вторую полипептидную цепь, обеспечивающие связывающий участок, полученный из Т-клеточного рецептора (ТКР), специфичного к пептидному эпитопу, ассоциированному с главным комплексом гистосовместимости (МНС), и связывающий участок, полученный из антитела, способного к привлечению иммунных эффекторных клеток человека за счет специфического связывания с поверхностным антигеном указанных клеток, а также к способам получения биспецифической молекулы полипептида и их применению.
EA202090250A 2018-04-16 2018-07-13 Усовершенствованная молекула полипептида с двойной специфичностью EA202090250A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658318P 2018-04-16 2018-04-16
PCT/EP2018/069151 WO2019012138A1 (en) 2017-07-14 2018-07-13 POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY

Publications (1)

Publication Number Publication Date
EA202090250A1 true EA202090250A1 (ru) 2020-05-08

Family

ID=70847669

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202090240A EA202090240A1 (ru) 2018-04-16 2018-07-13 Усовершенствованная молекула полипептида с двойной специфичностью
EA202090250A EA202090250A1 (ru) 2018-04-16 2018-07-13 Усовершенствованная молекула полипептида с двойной специфичностью

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202090240A EA202090240A1 (ru) 2018-04-16 2018-07-13 Усовершенствованная молекула полипептида с двойной специфичностью

Country Status (1)

Country Link
EA (2) EA202090240A1 (ru)

Also Published As

Publication number Publication date
EA202090240A1 (ru) 2020-05-08

Similar Documents

Publication Publication Date Title
MX2020011744A (es) Molecula de polipeptido con especificidad dual mejorada.
DOP2023000165A (es) Anticuerpos de unión a cd3
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
CO2020006905A2 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
CL2023000562A1 (es) Proteínas de unión a antígeno que se unen específicamente a mage-a
RU2016151235A (ru) Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
EA201590187A1 (ru) Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания
EA202091569A1 (ru) Моноклональные антитела и способы их применения
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada
CL2021001704A1 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
MX2023005313A (es) Anticuerpos fcrn y metodos de uso de estos.
RU2017124512A (ru) Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2022001380A (es) Anticuerpos de fcrn y metodos de uso de los mismos.
EA202090250A1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
PH12020500098A1 (en) Improved dual specific polypeptide molecule
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
WO2021016534A3 (en) Antigenic polypeptides and methods of use thereof
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением